AQR Capital Management
DAWN

AQR Capital Management’s Day One Biopharmaceuticals DAWN Stock Holding History

AQR Capital Management’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.53M Buy
444,467
+12,709
+3% +$179K ﹤0.01% 1363
2025
Q4 		$4.02M Buy
431,758
+323,281
+298% +$2.7M ﹤0.01% 1704
2025
Q3 		$765K Sell
108,477
-171,373
-61% -$1.18M ﹤0.01% 2585
2025
Q2 		$1.82M Sell
279,850
-338,777
-55% -$2.33M ﹤0.01% 1836
2025
Q1 		$4.91M Buy
618,627
+530,429
+601% +$5.71M 0.01% 1132
2024
Q4 		$1.12M Sell
88,198
-42,112
-32% -$586K ﹤0.01% 1830
2024
Q3 		$1.82M Buy
130,310
+17,290
+15% +$247K ﹤0.01% 1553
2024
Q2 		$1.56M Buy
113,020
+94,703
+517% +$1.39M ﹤0.01% 1564
2024
Q1 		$303K Buy
18,317
+8,159
+80% +$122K ﹤0.01% 2130
2023
Q4 		$148K Buy
+10,158
New +$123K ﹤0.01% 2251
2023
Q3 		– Sell
-14,404
Closed -$172K – 2329
2023
Q2 		$172K Buy
14,404
+1,348
+10% +$17.6K ﹤0.01% 2099
2023
Q1 		$175K Buy
13,056
+3,545
+37% +$69.2K ﹤0.01% 2071
2022
Q4 		$205K Buy
+9,511
New +$195K ﹤0.01% 2076

Other funds holding DAWN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
KC
Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

AQR Capital Management's DAWN Position: Q1 2026 in Review

AQR Capital Management increased its Day One Biopharmaceuticals (DAWN) stake by 2.9% in Q1 2026, buying an estimated $179K and bringing the position to 444,467 shares worth $9.53M. The position accounts for ﹤0.01% of the portfolio, ranked #1363.

AQR Capital Management first reported a position in DAWN in Q4 2022 and has held it in 13 quarters since. 206 funds tracked by Wall St. Rank hold DAWN as of Q1 2026.

  • AQR Capital Management held 444,467 shares of Day One Biopharmaceuticals worth $9.53M as of Q1 2026.
  • AQR Capital Management bought 12,709 Day One Biopharmaceuticals shares in Q1 2026, an estimated $179K.
  • Day One Biopharmaceuticals made up ﹤0.01% of AQR Capital Management's portfolio in Q1 2026, its #1363 holding.
  • AQR Capital Management first reported a position in Day One Biopharmaceuticals in Q4 2022 and has held it in 13 quarters since.
  • 206 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2026.

Based on AQR Capital Management's 13F filing for Q1 2026, filed 15 May 2026.